Headlands Technologies LLC Raises Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Headlands Technologies LLC boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 599.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,812 shares of the biopharmaceutical company’s stock after acquiring an additional 29,832 shares during the period. Headlands Technologies LLC’s holdings in Amicus Therapeutics were worth $328,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in Amicus Therapeutics in the third quarter valued at $55,000. Point72 Asset Management L.P. acquired a new position in shares of Amicus Therapeutics during the 3rd quarter worth about $13,530,000. Point72 DIFC Ltd purchased a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $704,000. Wellington Management Group LLP raised its position in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after acquiring an additional 2,856,101 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Amicus Therapeutics during the third quarter worth approximately $405,000.

Amicus Therapeutics Trading Down 6.3 %

Shares of FOLD stock opened at $7.50 on Friday. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The business’s 50 day moving average is $9.12 and its two-hundred day moving average is $9.86. Amicus Therapeutics, Inc. has a twelve month low of $7.39 and a twelve month high of $12.65. The company has a market capitalization of $2.30 billion, a P/E ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Analyst Ratings Changes

Several brokerages have commented on FOLD. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Wells Fargo & Company cut their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Morgan Stanley restated an “equal weight” rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.